表纸
市场调查报告书

披衣菌感染:全球临床实验检讨

Chlamydia Infections Global Clinical Trials Review, H2, 2018

出版商 GlobalData 商品编码 177202
出版日期 内容资讯 英文 84 Pages
订单完成后即时交付
价格
Back to Top
披衣菌感染:全球临床实验检讨 Chlamydia Infections Global Clinical Trials Review, H2, 2018
出版日期: 2018年12月31日内容资讯: 英文 84 Pages
简介

披衣菌感染是由非常细小的Chlamydia trachomatis(砂眼披衣菌)引起的性感染病(STI)。会影响颈椎、尿道、输卵管、子宫、鼻咽、副睾丸等部位。

本报告提供披衣菌感染的治疗药相关之临床实验调查分析,提供您临床实验数及受验人数,各阶段及Phase状况,有潜力企业,正在开发的治疗药的资讯,临床实验简介等相关的系统性资讯。

目录

简介

各地区的临床实验

  • 各国临床实验趋势
    • 亚太地区的主要国家
    • 欧洲的主要国家
    • 北美的主要国家
    • 中东·非洲的主要国家
    • 中南美的主要国家

G7各国的临床实验:感染性疾病临床实验上披衣菌感染所占的比例

G7各国的临床实验:Phase别

G7各国的临床实验:各阶段

E7各国的临床实验:感染性疾病临床实验上披衣菌感染所占的比例

E7各国的临床实验:Phase别

E7各国的临床实验:各阶段

各方面的临床实验

各阶段临床实验

评估项目别临床实验

未完成的临床实验

一定期间所采用的实验对象

赞助商类别临床实验

有潜力的赞助商

  • 披衣菌感染的治疗药临床实验的主要参与企业

有潜力药物

临床实验简介

  • 主要企业临床实验概要
    • kyorin制药集团
    • Endo International plc
    • Cempra Pharmaceuticals, Inc.
    • ActivBiotics Pharma, LLC
    • Actavis plc
  • 主要大学·研究机关·医院临床实验概要
    • University of California, San Francisco
    • Johns Hopkins University
    • Centers for Disease Control and Prevention
    • National Heart, Lung, and Blood Institute
    • University of Pittsburgh
    • The University of Melbourne
    • Washington University School of Medicine
    • London School of Hygiene & Tropical Medicine
    • Population Council
    • Barts and The London NHS Trust

主要的临床简介

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC5551CTIDB

GlobalData's clinical trial report, "Chlamydia Infections Global Clinical Trials Review, H2, 2018" provides an overview of Chlamydia Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents 2
    • List of Tables 3
    • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
    • Clinical Trials and Average Enrollment by Country 8
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
      • Top Five Countries Contributing to Clinical Trials in Europe 12
      • Top Countries Contributing to Clinical Trials in North America 13
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
      • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
    • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
    • Top Companies Participating in Chlamydia Infections Therapeutics Clinical Trials 31
  • Prominent Drugs 33
  • Clinical Trial Profile Snapshots 34
  • Appendix 82
    • Abbreviations 82
    • Definitions 82
    • Research Methodology 83
    • Secondary Research 83
    • About GlobalData 84
    • Contact Us 84
  • Source 84

List of Tables

  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Chlamydia Infections Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
  • Chlamydia Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 16
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 20
  • Chlamydia Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Chlamydia Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase, 2018* 23
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 24
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 28
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 30
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 32
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33

List of Figures

  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 16
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 19
  • Chlamydia Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Chlamydia Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase (%), 2018* 23
  • Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 24
  • Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 28
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 31
  • Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33
  • GlobalData Methodology 83
Back to Top